| Literature DB >> 35566050 |
Yassine Kaddouri1, Redouane Benabbes2, Sabir Ouahhoud2, Magda Abdellattif3, Belkheir Hammouti4, Rachid Touzani4.
Abstract
Bayoud disease affects date palms in North Africa and the Middle East, and many researchers have used various methods to fight it. One of those methods is the chemical use of synthetic compounds, which raises questions centred around the compounds and common features used to prepare targeted molecules. In this review, 100 compounds of tested small molecules, collected from 2002 to 2022 in Web of Sciences, were divided into ten different classes against the main cause of Bayoud disease pathogen Fusarium oxysporum f. sp. albedinis (F.o.a.) with structure-activity relationship (SAR) interpretations for pharmacophore site predictions as (δ-···δ-), where 12 compounds are the most efficient (one compound from each group). The compounds, i.e., (Z)-1-(1.5-Dimethyl-1H-pyrazole-3-yl)-3-hydroxy but-2-en-1-one 7, (Z)-3-(phenyl)-1-(1,5-dimethyl-1H-pyrazole-3-yl)-3-hydroxyprop-2-en-1-one 23, (Z)-1-(1,5-Dimethyl-1H-pyrazole-3-yl)-3-hydroxy-3-(pyridine-2-yl)prop-2-en-1-one 29, and 2,3-bis-[(2-hydroxy-2-phenyl)ethenyl]-6-nitro-quinoxaline 61, have antifungal pharmacophore sites (δ-···δ-) in common in N1---O4, whereas other compounds have only one δ- pharmacophore site pushed by the donor effect of the substituents on the phenyl rings. This specificity interferes in the biological activity against F.o.a. Further understanding of mechanistic drug-target interactions on this subject is currently underway.Entities:
Keywords: B-keto-enol; Bayoud; Fusarium oxysporum f. sp. albedinis; amino acid; imidazole; pyrazole; quinoxaline
Mesh:
Substances:
Year: 2022 PMID: 35566050 PMCID: PMC9099577 DOI: 10.3390/molecules27092698
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
IC50 values of the tested pyrazole- and imidazole-based derivatives tested against F.o.a.
| ID. | Structure | IC50 | |
|---|---|---|---|
| μg/mL | μM | ||
|
|
| 110.9 | 299.4 |
|
|
| 153.2 | 538.8 |
|
|
| 165.1 | 509.1 |
|
|
| 99.1 | 256.4 |
|
|
| 114.7 | 378.3 |
|
|
| 194.5 | 667.1 |
Compared with literary works, we found that the pyrazole skeleton and its derivatives exhibited excellent inhibitory activity against Fusarium oxysporum [66].
IC50 values of the tested βketo-enol pyridine and furan derivatives against F.o.a.
| ID | Structure | IC50 | |
|---|---|---|---|
| μg/mL | μM | ||
|
|
| 12.83 | |
|
|
| NS | NS |
|
|
| NS | NS |
|
|
| 17 | |
|
|
| 36 | |
|
|
| - | - |
|
|
| - | - |
|
|
| - | - |
|
|
| - | - |
|
|
| - | - |
|
|
| - | - |
Figure 1Antibacterial and antifungal pharmacophore sites for compound 7.
Volume is withdrawn, a diameter of the strain and inhibition percentages of the tested (Z)-3(3-bromophenyl)-1-(1,5-dimethyl-1H-pyrazole-3yl)-3-hydroxyprop-2-en-1-one derivatives 18–23 against F.o.a.
| ID | Structure | Volume Is Withdrawn (μL) | Diameter of the Strain in the Presence of the Drug (cm) | Inhibition (%) |
|---|---|---|---|---|
|
|
| 50 | 5.0 | 0 |
|
|
| 50 | 5.0 | 0 |
|
|
| 50 | 5.0 | 0 |
|
|
| 50 | 5.0 | 0 |
|
|
| 50 | 1.2 | 76 |
|
|
| 50 | 2.0 | 60 |
|
|
| 50 | 2.3 | 54 |
IC50 values of the tested βketo-enol pyrazolic derivatives against F.o.a.
| ID | Structure | IC50 | |
|---|---|---|---|
| μg/mL | μM | ||
|
|
| - | - |
|
|
| 260.74 | 71 |
|
|
| - | - |
|
|
| - | - |
|
|
| 193.31 | 48.00 |
|
|
| 60.84 | 14.80 |
|
|
| 181.30 | 53.00 |
IC50 values of the tested imidazothiazole derivatives against F.o.a.
| ID | Structure | IC50 (μg/mL) |
|---|---|---|
|
|
| 50.00 |
|
|
| 70.00 |
|
|
| 20.00 |
|
|
| 60.00 |
|
|
| 50.00 |
IC50 values of the tested pyrazolic compounds against F.o.a.
| ID | Structure | IC50 (μM) |
|---|---|---|
|
|
| - |
|
|
| 751 |
|
|
| 2507 |
|
|
| 406 |
|
|
| 398 |
|
|
| 333 |
|
|
| 2755 |
|
|
| 2550 |
|
|
| 2486 |
|
|
| 2614 |
|
|
| 1223 |
|
|
| 697 |
|
|
| 2856 |
|
|
| 2322 |
|
|
| 86 |
|
|
| 662 |
|
|
| 2592 |
|
|
| 284 |
|
|
| - |
|
|
| 168 |
Percent growth inhibition at different concentrations for quinoxaline compounds tested against F.o.a.
| ID | Structure | Percent Growth Inhibition (Concentration, mg/L) | ||
|---|---|---|---|---|
| C1 | C2 | C3 | ||
|
|
| 9 (20) | 7 (40) | 22 (80) |
|
|
| 9 (60) | 15 (120) | 15 (180) |
|
|
| 17 (60) | 17 (120) | 19 (180) |
|
|
| 21 | 32 | 35 (180) |
|
|
| 15 (34) | 31 (67) | 33 (134) |
|
|
| 29 (18) | 31 (36) | 51 (72) |
Linear growth and inhibitory sporulation rates of benzimidazole-1,2,3-triazole hybrid molecules tested against F.o.a.
| ID | Structure | Linear Growth-Inhibitory Rates (%) | Sporulation Inhibitory Rates (%) |
|---|---|---|---|
|
|
| 3.02 ± 0.96 | −5.85 ± 0.04 |
|
|
| −1.59 ± 0.05 | 16.36 ± 0.2 |
|
|
| 2.7 ± 0.16 | −34.79 ± 0.72 |
|
|
| −0.16 ± 0.02 | 21.94 ± 0.26 |
|
|
| 17.01 ± 0.96 | 30.62 ± 0.5 |
|
|
| 2.3 ± 0.29 | −77.59 ± 2.64 |
|
|
| −1.41 ± 0.3 | −61.05 ± 1.34 |
|
|
| −14 ± 0.05 | −48.72 ± 2.35 |
M.I.C. values of N,N′-bipyrazole piperazine derivatives tested against F.o.a.
| ID | Structure | M.I.C. | |
|---|---|---|---|
| μg/mL | μM | ||
|
|
| 10 | 33.06 |
|
|
| 5 | 11.94 |
|
|
| 10 | 32.85 |
|
|
| 20 | 47.56 |
M.I.C. values of bipyrazolic tripodal compounds tested against F.o.a.
| ID | Structure | M.I.C. | |
|---|---|---|---|
| μg/mL | μM | ||
|
|
| 2.5 | 8.05 |
|
|
| 5 | 11.73 |
|
|
| 2.5 | 8.08 |
|
|
| 40 | 94.7 |
|
|
| 2.5 | 7.05 |
|
|
| 5 | 10.63 |
|
|
| 40 | 123.84 |
|
|
| 80 | 182.14 |
M.I.C. values of Schiff base derivatives compounds tested against F.o.a.
| ID | Structure | MIC (μg/mL) |
|---|---|---|
|
|
| 0.10 |
|
|
| 0.90 |
|
|
| 0.02 |
|
|
| 0.25 |
|
|
| 0.30 |
|
|
| 0.04 |
|
|
| 0.04 |
|
|
| 0.12 |
|
|
| 0.25 |
|
|
| 0.20 |
|
|
| 0.08 |
|
|
| 0.04 |
MIC values of amino acids pyrazole compound tested against F.o.a.
| ID | Structure | MIC (mg/L) |
|---|---|---|
|
|
| - |
|
|
| - |
|
|
| 17 |
|
|
| 15 |
|
|
| 0.3 |
|
|
| 10 |
|
|
| 0.5 |
Figure 2Chemical structure of the best active compounds from the group.